Accelerate Diagnostics, Inc. (AXDX) Analysts See $-0.37 EPS

July 11, 2018 - By Peter Erickson

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) LogoInvestors sentiment increased to 1.1 in 2018 Q1. Its up 0.29, from 0.81 in 2017Q4. It increased, as 10 investors sold Accelerate Diagnostics, Inc. shares while 29 reduced holdings. 14 funds opened positions while 29 raised stakes. 20.31 million shares or 2.07% more from 19.90 million shares in 2017Q4 were reported.
California-based Reilly Advsrs Ltd Liability has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Utd Capital Advisers Ltd Limited Liability Company holds 12,226 shares or 0% of its portfolio. Patten Group Inc stated it has 0.03% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). The California-based California State Teachers Retirement Systems has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Rhumbline Advisers holds 0% or 25,356 shares in its portfolio. Group Incorporated One Trading Ltd Partnership holds 26,887 shares or 0.01% of its portfolio. Artal Gru Sa, a Luxembourg-based fund reported 500,000 shares. Hightower Advsrs Limited Liability has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). New York State Common Retirement Fund, New York-based fund reported 27,900 shares. Miura Management Ltd Liability Company invested 0.91% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). New York-based Lombard Odier Asset Mngmt (Usa) has invested 0.16% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Bnp Paribas Arbitrage has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Cutter & Com Brokerage Incorporated has invested 0.24% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Legal And General Gp Plc holds 4,903 shares or 0% of its portfolio. Moreover, State Street has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

Since February 20, 2018, it had 7 insider buys, and 0 selling transactions for $4.73 million activity.

Analysts expect Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report $-0.37 EPS on August, 2.They anticipate $0.06 EPS change or 19.35 % from last quarter’s $-0.31 EPS. After having $-0.37 EPS previously, Accelerate Diagnostics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.24% or $0.05 during the last trading session, reaching $21. About 73,875 shares traded. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has declined 29.70% since July 12, 2017 and is downtrending. It has underperformed by 42.27% the S&P500.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.13 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

More news for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were recently published by: Benzinga.com, which released: “30 Stocks Moving In Thursday’s Pre-Market Session” on June 21, 2018. Benzinga.com‘s article titled: “4 Stocks That Have Been On Strong Up Trends In June” and published on June 25, 2018 is yet another important article.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>